# Dong-Wan Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/59615/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 308 papers | 35,621 citations | 16451 64 h-index | 3579 181 g-index |
| 310 all docs | 310 docs citations | 310 times ranked | 24952 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550. | 13.7 | 5,456 |
| 2 | Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer. New England Journal of Medicine, 2013, 368, 2385-2394. | 27.0 | 3,181 |
| 3 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177. | 27.0 | 2,808 |
| 4 | Alectinib versus Crizotinib in Untreated ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 829-838. | 27.0 | 1,858 |
| 5 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discovery, 2014, 4, 1046-1061. | 9.4 | 1,655 |
| 6 | Ceritinib inALK-Rearranged Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2014, 370, 1189-1197. | 27.0 | 1,367 |
| 7 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncology, The, 2012, 13, 1011-1019. | 10.7 | 1,176 |
| 8 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncology, The, 2016, 17, 577-589. | 10.7 | 950 |
| 9 | Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Nonâ€“Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2005, 23, 2493-2501. | 1.6 | 736 |
| 10 | Brigatinib versus Crizotinib in ALK-Positive Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2027-2039. | 27.0 | 691 |
| 11 | First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 2020, 383, 2018-2029. | 27.0 | 592 |
| 12 | Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clinical Cancer Research, 2016, 22, 5130-5140. | 7.0 | 554 |
| 13 | Alectinib in Crizotinib-Refractory ALK-Rearranged Nonâ€“Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology, 2016, 34, 661-668. | 1.6 | 548 |
| 14 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2490-2498. | 1.6 | 506 |
| 15 | Osimertinib in Pretreated T790M-Positive Advanced Nonâ€“Small-Cell Lung Cancer: AURA Study Phase II Extension Component. Journal of Clinical Oncology, 2017, 35, 1288-1296. | 1.6 | 470 |
| 16 | Osimertinib As First-Line Treatment of EGFR Mutationâ€“Positive Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 841-849. | 1.6 | 423 |
| 17 | Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncology, The, 2016, 17, 452-463. | 10.7 | 418 |
| 18 | Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology, 2017, 35, 3823-3829. | 1.6 | 413 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. Journal of Clinical Oncology, 2017, 35, 3065-3074. | 1.6 | 349 |
| 20 | Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discovery, 2018, 8, 1227-1236. | 9.4 | 321 |
| 21 | Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402. | 1.6 | 320 |
| 22 | Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2251-2258. | 1.6 | 308 |
| 23 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factorâ€“Dysregulated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 3101-3109. | 1.6 | 252 |
| 24 | Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1405-1411. | 1.6 | 230 |
| 25 | Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€“Naive ALK-Positive Nonâ€“Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Journal of Clinical Oncology, 2020, 38, 3592-3603. | 1.6 | 224 |
| 26 | Osimertinib in Patients With Epidermal Growth Factor Receptor Mutationâ€“Positive Nonâ€“Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. Journal of Clinical Oncology, 2020, 38, 538-547. | 1.6 | 221 |
| 27 | Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research, 2016, 22, 2261-2270. | 7.0 | 217 |
| 28 | Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Nonâ€“Small-Cell Lung Cancer: KCSG-LU05-04. Journal of Clinical Oncology, 2015, 33, 2660-2666. | 1.6 | 215 |
| 29 | Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€'Positive, Advanced Nonâ€'Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of Clinical Oncology, 2020, 38, 1580-1590. | 1.6 | 189 |
| 30 | Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 4079-4085. | 1.6 | 171 |
| 31 | Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT) Tj ETQq1 1 0.784314 rgBT /Overlock 8, 1132-1143. | 10.7 | 169 |
| 32 | Brigatinib Versus Crizotinib in ALK Inhibitorâ€“Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. Journal of Thoracic Oncology, 2021, 16, 2091-2108. | 1.1 | 156 |
| 33 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790Mâ€“Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. Journal of Thoracic Oncology, 2019, 14, 933-939. | 1.1 | 152 |
| 34 | Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1474-1480. | 1.1 | 148 |
| 35 | Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 415-422. | 1.1 | 147 |
| 36 | ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Nonâ€“Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, 1357-1367. | 1.1 | 144 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Modern Pathology, 2015, 28, 1154-1166. | 5.5 | 143 |
| 38 | Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1718-1732. | 1.1 | 141 |
| 39 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Nonâ€“Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor. JAMA - Journal of the American Medical Association, 2014, 311, 1430. | 7.4 | 136 |
| 40 | Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget, 2016, 7, 6984-6993. | 1.8 | 134 |
| 41 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitorâ€“Resistant, EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2022, 12, 74-89. | 9.4 | 133 |
| 42 | Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer, 2007, 58, 112-115. | 2.0 | 132 |
| 43 | Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunology, Immunotherapy, 2018, 67, 459-470. | 4.2 | 132 |
| 44 | Phase I Study of Random Healthy Donorâ€“Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer Immunology Research, 2016, 4, 215-224. | 3.4 | 128 |
| 45 | PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget, 2016, 7, 15901-15914. | 1.8 | 125 |
| 46 | EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1Î± and STAT3. OncoImmunology, 2016, 5, e1108514. | 4.6 | 124 |
| 47 | Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Nonâ€“Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. Journal of Clinical Oncology, 2018, 36, 2693-2701. | 1.6 | 124 |
| 48 | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer, 2009, 65, 80-84. | 2.0 | 118 |
| 49 | Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology, 2016, 77, 767-776. | 2.3 | 118 |
| 50 | Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2379-2387. | 7.0 | 116 |
| 51 | Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1433-1441. | 10.7 | 114 |
| 52 | Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1069-1074. | 1.1 | 110 |
| 53 | Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2016, 17, 263-270.e2. | 2.6 | 107 |
| 54 | Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 2020, 15, 404-415. | 1.1 | 102 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 2014, 19, 594-600. | 2.2 | 92 |
| 56 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respiratory Medicine,the, 2017, 5, 891-902. | 10.7 | 92 |
| 57 | Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1â€“2 study. Lancet Oncology, The, 2019, 20, 1681-1690. | 10.7 | 92 |
| 58 | Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219. | 4.5 | 87 |
| 59 | Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitorâ€“resistant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8009-8009. | 1.6 | 81 |
| 60 | AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Science Translational Medicine, 2016, 8, 368ra172. | 12.4 | 78 |
| 61 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560. | 1.1 | 75 |
| 62 | Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9008-9008. | 1.6 | 75 |
| 63 | Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, 1794-1806. | 1.1 | 69 |
| 64 | Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. Oncotarget, 2017, 8, 97920-97927. | 1.8 | 69 |
| 65 | Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for an Effective Screening Strategy for These Tumors. Journal of Thoracic Oncology, 2011, 6, 905-912. | 1.1 | 66 |
| 66 | Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer, 2019, 19, 19. | 2.6 | 66 |
| 67 | Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7533-7533. | 1.6 | 66 |
| 68 | CPR or DNR? End-of-life decision in Korean cancer patients: a single centerâ€™s experience. Supportive Care in Cancer, 2006, 14, 103-108. | 2.2 | 65 |
| 69 | Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. Journal of Neuro-Oncology, 2012, 106, 303-313. | 2.9 | 64 |
| 70 | Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.. Journal of Clinical Oncology, 2017, 35, 2020-2020. | 1.6 | 63 |
| 71 | Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer, 2013, 79, 242-247. | 2.0 | 62 |
| 72 | Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 576-584. | 1.1 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Advanced-Stage Nonâ€“Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1134-1155. | 1.1 | 61 |
| 74 | Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.. Journal of Clinical Oncology, 2016, 34, 9002-9002. | 1.6 | 59 |
| 75 | Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.. Journal of Clinical Oncology, 2015, 33, 7502-7502. | 1.6 | 58 |
| 76 | Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study).. Journal of Clinical Oncology, 2019, 37, 9011-9011. | 1.6 | 58 |
| 77 | Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9515-9515. | 1.6 | 57 |
| 78 | Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open, 2018, 3, e000332. | 4.5 | 55 |
| 79 | Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naÃ¯ve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.. Journal of Clinical Oncology, 2021, 39, 9006-9006. | 1.6 | 55 |
| 80 | A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer. British Journal of Cancer, 2021, 124, 383-390. | 6.4 | 54 |
| 81 | Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9512-9512. | 1.6 | 54 |
| 82 | Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Scientific Reports, 2021, 11, 19712. | 3.3 | 54 |
| 83 | Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1â€“Expressing NSCLC. Journal of Thoracic Oncology, 2019, 14, 793-801. | 1.1 | 50 |
| 84 | Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2018, 50, 691-700. | 3.0 | 50 |
| 85 | Comparative analyses of overall survival in patients with anaplastic lymphoma kinaseâ€positive and matched wildâ€type advanced nonsmall cell lung cancer. Cancer, 2012, 118, 3579-3586. | 4.1 | 49 |
| 86 | Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute. Cancer Research and Treatment, 2015, 47, 555-563. | 3.0 | 49 |
| 87 | Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2013, 45, 325-333. | 3.0 | 49 |
| 88 | Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Research and Treatment, 2019, 51, 951-962. | 3.0 | 48 |
| 89 | Remarkable Tumor Response to Crizotinib in a 14-Year-Old Girl With ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, e147-e150. | 1.6 | 47 |
| 90 | First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Nonâ€“small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. Clinical Lung Cancer, 2019, 20, 331-338.e4. | 2.6 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respiratory Medicine,the, 2020, 8, 561-572. | 10.7 | 47 |
| 92 | Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS ONE, 2018, 13, e0189766. | 2.5 | 46 |
| 93 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. European Journal of Cancer, 2014, 50, 2219-2230. | 2.8 | 44 |
| 94 | MET amplification, protein expression, and mutations in pulmonary adenocarcinoma. Lung Cancer, 2015, 90, 381-387. | 2.0 | 44 |
| 95 | The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Cancer Research and Treatment, 2016, 48, 907-916. | 3.0 | 44 |
| 96 | Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. American Journal of Pathology, 2017, 187, 980-986. | 3.8 | 44 |
| 97 | First-line crizotinib versus pemetrexedâ€“cisplatin or pemetrexedâ€“carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). Journal of Clinical Oncology, 2014, 32, 8002-8002. | 1.6 | 44 |
| 98 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitorâ€“Refractory ALK-Positive or ROS1-Positive NSCLC. Journal of Thoracic Oncology, 2020, 15, 1484-1496. | 1.1 | 43 |
| 99 | Proportion and clinical features of never-smokers with non-small cell lung cancer. Chinese Journal of Cancer, 2017, 36, 20. | 4.9 | 42 |
| 100 | Ceritinib in patients with advanced anaplastic lymphoma kinaseâ€“rearranged anaplastic large-cell lymphoma. Blood, 2015, 126, 1257-1258. | 1.4 | 40 |
| 101 | Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209. | 1.1 | 40 |
| 102 | Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. Theranostics, 2020, 10, 10838-10848. | 10.0 | 39 |
| 103 | Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology, 2014, 32, 8011-8011. | 1.6 | 39 |
| 104 | A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer, 2011, 71, 65-69. | 2.0 | 38 |
| 105 | Surrogate decision-making in Korean patients with advanced cancer: a longitudinal study. Supportive Care in Cancer, 2013, 21, 183-190. | 2.2 | 38 |
| 106 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. Korean Journal of Internal Medicine, 2016, 31, 570-578. | 1.7 | 38 |
| 107 | A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer, 2019, 136, 122-128. | 2.0 | 38 |
| 108 | Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study. Oncologist, 2019, 24, e740-e748. | 3.7 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).. Journal of Clinical Oncology, 2018, 36, 9009-9009. | 1.6 | 38 |
| 110 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. Journal of Thoracic Oncology, 2020, 15, 324-343. | 1.1 | 34 |
| 111 | Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.. Journal of Clinical Oncology, 2013, 31, 8010-8010. | 1.6 | 34 |
| 112 | Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. Journal of Clinical Oncology, 2019, 37, 6018-6018. | 1.6 | 34 |
| 113 | Immunogenicity of Influenza Vaccination in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Clinical Infectious Diseases, 2020, 71, 422-425. | 5.8 | 32 |
| 114 | Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1â€“Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clinical and Research Reports, 2021, 2, 100205. | 1.1 | 32 |
| 115 | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 670-675. | 3.0 | 32 |
| 116 | Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. BMC Cancer, 2016, 16, 116. | 2.6 | 31 |
| 117 | Generalization and representativeness of phase III immune checkpoint blockade trials in nonâ€small cell lung cancer. Thoracic Cancer, 2018, 9, 736-744. | 1.9 | 31 |
| 118 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1569-1579. | 2.5 | 31 |
| 119 | 2020 Clinical Practice Guideline for Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions: A Consensus Statement and Recommendations of the Korean Society of Thoracic Radiology. Korean Journal of Radiology, 2021, 22, 263. | 3.4 | 31 |
| 120 | Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.. Journal of Clinical Oncology, 2014, 32, 8017-8017. | 1.6 | 31 |
| 121 | Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer, 2016, 16, 170. | 2.6 | 30 |
| 122 | MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics. Lung Cancer, 2017, 106, 131-137. | 2.0 | 30 |
| 123 | Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9020-9020. | 1.6 | 30 |
| 124 | A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. Oncologist, 2019, 24, 20. | 3.7 | 29 |
| 125 | Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study. Journal of Thoracic Oncology, 2021, 16, 259-268. | 1.1 | 29 |
| 126 | First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3007-3007. | 1.6 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Research, 2015, 35, 175-82. | 1.1 | 29 |
| 128 | Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. Journal of Thoracic Oncology, 2019, 14, 1556-1566. | 1.1 | 28 |
| 129 | Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab Â± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).. Journal of Clinical Oncology, 2021, 39, 9047-9047. | 1.6 | 28 |
| 130 | First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers.. Journal of Clinical Oncology, 2012, 30, 7530-7530. | 1.6 | 28 |
| 131 | Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7543-7543. | 1.6 | 28 |
| 132 | Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2015, 33, 8084-8084. | 1.6 | 28 |
| 133 | Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2016, 34, 9044-9044. | 1.6 | 28 |
| 134 | Geriatric Nutritional Risk Index as a prognostic marker in patients with extensiveâ€stage disease small cell lung cancer: Results from a randomized controlled trial. Thoracic Cancer, 2020, 11, 62-71. | 1.9 | 27 |
| 135 | BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.. Journal of Clinical Oncology, 2016, 34, 9055-9055. | 1.6 | 27 |
| 136 | Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. Cancer Research and Treatment, 2017, 49, 416-422. | 3.0 | 27 |
| 137 | Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Nonâ€“Small-Cell Lung Cancer with Activating EGFR Mutation. Journal of Thoracic Oncology, 2015, 10, 1189-1194. | 1.1 | 26 |
| 138 | Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. Korean Journal of Internal Medicine, 2016, 31, 1140-1149. | 1.7 | 26 |
| 139 | Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive nonâ€“small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 2017, 82, 27-33. | 2.8 | 25 |
| 140 | Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. Journal of Clinical Oncology, 2016, 34, 9007-9007. | 1.6 | 25 |
| 141 | Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.. Journal of Clinical Oncology, 2019, 37, 3017-3017. | 1.6 | 25 |
| 142 | Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2021, 39, 9007-9007. | 1.6 | 24 |
| 143 | Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8003-8003. | 1.6 | 24 |
| 144 | Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instabilityâ€“high (MSI-H) tumors.. Journal of Clinical Oncology, 2019, 37, 670-670. | 1.6 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.. Journal of Clinical Oncology, 2022, 40, 105-105. | 1.6 | 24 |
| 146 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. British Journal of Cancer, 2018, 118, 38-42. | 6.4 | 23 |
| 147 | Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-NaÃ¯ve Korean Patients with Extensive-Disease Small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 119-127. | 3.0 | 23 |
| 148 | Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors. Journal of Korean Medical Science, 2014, 29, 1094. | 2.5 | 22 |
| 149 | Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer, 2018, 122, 234-242. | 2.0 | 22 |
| 150 | Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72. | 2.0 | 22 |
| 151 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2020, 139, 22-27. | 2.0 | 22 |
| 152 | Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2016, 22, 8389. | 3.3 | 22 |
| 153 | Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 520-528. | 1.1 | 21 |
| 154 | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. Lung Cancer, 2018, 123, 14-21. | 2.0 | 21 |
| 155 | Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatanib plus paclitaxel (P) versus investigatorâ€™s choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatanibâ€”LUX-Lung 5 (LL5).. Journal of Clinical Oncology, 2014, 32, 8019-8019. | 1.6 | 21 |
| 156 | Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).. Journal of Clinical Oncology, 2016, 34, 9003-9003. | 1.6 | 21 |
| 157 | KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. Korean Journal of Internal Medicine, 2017, 32, 514-522. | 1.7 | 21 |
| 158 | Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2014, 46, 323-330. | 3.0 | 21 |
| 159 | Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations. Cancer Research and Treatment, 2015, 47, 630-637. | 3.0 | 21 |
| 160 | A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. Oncologist, 2015, 20, 1119-1120. | 3.7 | 20 |
| 161 | Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations. Clinical Lung Cancer, 2016, 17, 245-252.e1. | 2.6 | 20 |
| 162 | Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Nonâ€“Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. Clinical Lung Cancer, 2017, 18, e169-e178. | 2.6 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection. European Radiology, 2018, 28, 861-868. | 4.5 | 20 |
| 164 | Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Research and Treatment, 2019, 51, 1231-1240. | 3.0 | 20 |
| 165 | Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Nonâ€“Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology, 2014, 9, 1523-1531. | 1.1 | 19 |
| 166 | Korean Cancer Patientsâ€™ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate. Cancer Research and Treatment, 2017, 49, 1033-1043. | 3.0 | 19 |
| 167 | Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. Cancer Research and Treatment, 2016, 48, 88-97. | 3.0 | 19 |
| 168 | ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Nonâ€“Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clinical Cancer Research, 2022, 28, 2506-2516. | 7.0 | 19 |
| 169 | The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 2135-2142. | 2.5 | 18 |
| 170 | Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer. Cancer Biomarkers, 2016, 16, 425-433. | 1.7 | 18 |
| 171 | Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. Journal of Clinical Oncology, 2015, 33, 8008-8008. | 1.6 | 18 |
| 172 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2015, 33, 8013-8013. | 1.6 | 18 |
| 173 | AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.. Journal of Clinical Oncology, 2015, 33, 8016-8016. | 1.6 | 18 |
| 174 | Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ nonâ€“small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.. Journal of Clinical Oncology, 2018, 36, 9061-9061. | 1.6 | 18 |
| 175 | Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.. Journal of Clinical Oncology, 2020, 38, 9518-9518. | 1.6 | 18 |
| 176 | Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. Lung Cancer, 2014, 86, 363-368. | 2.0 | 17 |
| 177 | Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2016, 142, 873-883. | 2.5 | 17 |
| 178 | Olmutinib in T790Mâ€positive nonâ€“small cell lung cancer after failure of firstâ€line epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416. | 4.1 | 17 |
| 179 | Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. Scientific Reports, 2021, 11, 2514. | 3.3 | 17 |
| 180 | Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.. Journal of Clinical Oncology, 2012, 30, 7600-7600. | 1.6 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naÃ¯ve, EGFRm NSCLC with CNS metastases.. Journal of Clinical Oncology, 2017, 35, 2006-2006. | 1.6 | 17 |
| 182 | A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/Tâ€Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group. Oncologist, 2014, 19, 1129-1130. | 3.7 | 16 |
| 183 | Phase <scp>II</scp> study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: <scp>KCSGâ€LU16</scp>â€07. Thoracic Cancer, 2020, 11, 3482-3489. | 1.9 | 16 |
| 184 | Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 1859-1871. | 1.1 | 16 |
| 185 | A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.. Journal of Clinical Oncology, 2016, 34, 9013-9013. | 1.6 | 16 |
| 186 | Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008. | 1.6 | 16 |
| 187 | Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in nonâ€small cell lung cancer. International Journal of Oncology, 2020, 56, 559-567. | 3.3 | 16 |
| 188 | NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors. Cytotherapy, 2019, 21, 603-611. | 0.7 | 15 |
| 189 | Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer. Clinical Lung Cancer, 2019, 20, e442-e451. | 2.6 | 15 |
| 190 | MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8029-8029. | 1.6 | 15 |
| 191 | A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).. Journal of Clinical Oncology, 2018, 36, 2513-2513. | 1.6 | 15 |
| 192 | Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. Head and Neck, 2016, 38, 277-284. | 2.0 | 14 |
| 193 | Clinical Application of Next-Generation Sequencingâ€“Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. Molecular Cancer Therapeutics, 2020, 19, 937-944. | 4.1 | 14 |
| 194 | Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 9022-9022. | 1.6 | 14 |
| 195 | Factors associated with better overall survival (OS) in patients with previously treated, PD-L1â€“expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010.. Journal of Clinical Oncology, 2017, 35, 9090-9090. | 1.6 | 14 |
| 196 | The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer. Cancer Research and Treatment, 2018, 50, 720-728. | 3.0 | 14 |
| 197 | Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated nonâ€“small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.. Journal of Clinical Oncology, 2022, 40, 102-102. | 1.6 | 14 |
| 198 | A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer, 2016, 93, 1-8. | 2.0 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Supportive Care in Cancer, 2017, 25, 429-437. | 2.2 | 13 |
| 200 | A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer. British Journal of Cancer, 2021, 124, 713-720. | 6.4 | 13 |
| 201 | Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 3047-3047. | 1.6 | 13 |
| 202 | AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.. Journal of Clinical Oncology, 2015, 33, 8000-8000. | 1.6 | 13 |
| 203 | Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status.. Journal of Clinical Oncology, 2016, 34, 9060-9060. | 1.6 | 13 |
| 204 | Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 699-711. | 2.8 | 12 |
| 205 | Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1.. Journal of Clinical Oncology, 2016, 34, 9064-9064. | 1.6 | 12 |
| 206 | Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 11506-11506. | 1.6 | 12 |
| 207 | Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.. Journal of Clinical Oncology, 2017, 35, 2069-2069. | 1.6 | 12 |
| 208 | Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?. Korean Journal of Internal Medicine, 2019, 34, 1313-1323. | 1.7 | 12 |
| 209 | Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 2017, 106, 76-82. | 2.0 | 11 |
| 210 | A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01). Oncotarget, 2017, 8, 15943-15951. | 1.8 | 11 |
| 211 | First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).. Journal of Clinical Oncology, 2016, 34, 9046-9046. | 1.6 | 11 |
| 212 | EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. Japanese Journal of Clinical Oncology, 2011, 41, 548-554. | 1.3 | 10 |
| 213 | Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. Yonsei Medical Journal, 2016, 57, 795. | 2.2 | 10 |
| 214 | Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1â€“Positive NSCLC.. Journal of Clinical Oncology, 2016, 34, 9015-9015. | 1.6 | 10 |
| 215 | ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036. | 1.6 | 10 |
| 216 | Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naÃ¯ve EGFR-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9094-9094. | 1.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, TPS3654-TPS3654. | 1.6 | 10 |
| 218 | Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2015, 30, 891-898. | 1.7 | 10 |
| 219 | Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea. Cancer Research and Treatment, 2020, 52, 1112-1119. | 3.0 | 10 |
| 220 | Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era. Cancer Research and Treatment, 2016, 48, 304-311. | 3.0 | 9 |
| 221 | Comparison of Native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone, in Extranodal NK/T-Cell Lymphoma, Nasal Type. Cancer Research and Treatment, 2018, 50, 670-680. | 3.0 | 9 |
| 222 | The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinaseâ€positive nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 2117-2123. | 1.9 | 9 |
| 223 | Real-world use of osimertinib in nonâ€“small cell lung cancer: ASTRIS study Korean subgroup analysis. Current Medical Research and Opinion, 2020, 36, 477-482. | 1.9 | 9 |
| 224 | Risk stratification of symptomatic brain metastases by clinical and FDG PET parameters for selective use of prophylactic cranial irradiation in patients with extensive disease of small cell lung cancer. Radiotherapy and Oncology, 2020, 143, 81-87. | 0.6 | 9 |
| 225 | A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica, 2021, 106, 2277-2280. | 3.5 | 9 |
| 226 | Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.. Journal of Clinical Oncology, 2021, 39, 9089-9089. | 1.6 | 9 |
| 227 | Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.. Journal of Clinical Oncology, 2016, 34, 9066-9066. | 1.6 | 9 |
| 228 | Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.. Journal of Clinical Oncology, 2017, 35, e20504-e20504. | 1.6 | 9 |
| 229 | Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP. Korean Journal of Internal Medicine, 2019, 34, 885-893. | 1.7 | 9 |
| 230 | A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. Cancer Research and Treatment, 2014, 46, 19-26. | 3.0 | 9 |
| 231 | Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). JTO Clinical and Research Reports, 2022, 3, 100261. | 1.1 | 9 |
| 232 | Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.. Journal of Clinical Oncology, 2022, 40, 9017-9017. | 1.6 | 9 |
| 233 | Virtual reality-assisted localization and three-dimensional printing-enhanced multidisciplinary decision to treat radiologically occult superficial endobronchial lung cancer. Thoracic Cancer, 2018, 9, 1525-1527. | 1.9 | 8 |
| 234 | Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Letters, 2020, 495, 135-144. | 7.2 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy. Cancer Immunology, Immunotherapy, 2021, 70, 1605-1617. | 4.2 | 8 |
| 236 | Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study. Cancer Research, 2021, 81, CT163-CT163. | 0.9 | 8 |
| 237 | Tumor <scp>LAG</scp>â€3 and <scp>NYâ€ESO</scp>â€1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 619-630. | 1.9 | 8 |
| 238 | Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2018, 59, 202. | 2.2 | 7 |
| 239 | Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8078-8078. | 1.6 | 7 |
| 240 | Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.. Journal of Clinical Oncology, 2016, 34, 9024-9024. | 1.6 | 7 |
| 241 | Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.. Journal of Clinical Oncology, 2017, 35, 9085-9085. | 1.6 | 7 |
| 242 | A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8575-8575. | 1.6 | 7 |
| 243 | Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study.. Journal of Clinical Oncology, 2020, 38, 9571-9571. | 1.6 | 7 |
| 244 | The presence of extrathoracic metastasis is more prognostic of survival than Masaoka stage (IVa/IVb) in metastatic thymic epithelial tumor: A retrospective cohort study. Lung Cancer, 2014, 85, 320-325. | 2.0 | 6 |
| 245 | <p>Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (<em>ALK</em>)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies</p>. Lung Cancer: Targets and Therapy, 2019, Volume 10, 125-130. | 2.7 | 6 |
| 246 | Antiâ€“cytotoxic T-lymphocyteâ€“associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. Lung Cancer, 2021, 159, 162-170. | 2.0 | 6 |
| 247 | A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 3076-3076. | 1.6 | 6 |
| 248 | Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. Journal of Clinical Oncology, 2012, 30, 7596-7596. | 1.6 | 6 |
| 249 | Tolerability, efficacy and recommended phase II dose (RP2D) of tepotinib plus gefitinib in Asian patients with c-Met-positive/EGFR-mutant NSCLC: Phase Ib data.. Journal of Clinical Oncology, 2016, 34, e20501-e20501. | 1.6 | 6 |
| 250 | Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. Journal of Clinical Oncology, 2017, 35, LBA9008-LBA9008. | 1.6 | 6 |
| 251 | Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 1116-1124. | 1.7 | 6 |
| 252 | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. ESMO Open, 2019, 4, e000575. | 4.5 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9072-9072. | 1.6 | 5 |
| 254 | Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 169-169. | 1.6 | 5 |
| 255 | Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. Cancer Research and Treatment, 2017, 49, 129-140. | 3.0 | 5 |
| 256 | Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer. Korean Journal of Internal Medicine, 2021, 36, 975-984. | 1.7 | 5 |
| 257 | Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues. Cancer Immunology, Immunotherapy, 2021, 70, 1755-1769. | 4.2 | 4 |
| 258 | Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment. Cancer Research and Treatment, 2021, 53, 1195-1203. | 3.0 | 4 |
| 259 | Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.. Journal of Clinical Oncology, 2021, 39, 2579-2579. | 1.6 | 4 |
| 260 | PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. Journal of Clinical Oncology, 2012, 30, 10009-10009. | 1.6 | 4 |
| 261 | Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. Journal of Clinical Oncology, 2016, 34, 3030-3030. | 1.6 | 4 |
| 262 | Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial.. Journal of Clinical Oncology, 2019, 37, 9026-9026. | 1.6 | 4 |
| 263 | Nazartinib (EGF816) in patients with treatment-naÃ¯ve EGFR-mutant non-small cell lung cancer (NSCLC): Updated phase II results.. Journal of Clinical Oncology, 2020, 38, 9574-9574. | 1.6 | 4 |
| 264 | Overcoming the impact of the COVIDâ€19 pandemic on oncology early phase trials and drug development in Asiaâ€"Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 388-395. | 1.1 | 3 |
| 265 | Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.. Journal of Clinical Oncology, 2021, 39, 9071-9071. | 1.6 | 3 |
| 266 | A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).. Journal of Clinical Oncology, 2012, 30, 7599-7599. | 1.6 | 3 |
| 267 | GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) Â± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology, 2016, 34, TPS9109-TPS9109. | 1.6 | 3 |
| 268 | Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.. Journal of Clinical Oncology, 2017, 35, e20502-e20502. | 1.6 | 3 |
| 269 | Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.. Journal of Clinical Oncology, 2017, 35, e20503-e20503. | 1.6 | 3 |
| 270 | Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.. Journal of Clinical Oncology, 2020, 38, 9572-9572. | 1.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment, 2015, 47, 182-188. | 3.0 | 3 |
| 272 | The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy. Cancer Research and Treatment, 2019, 51, 169-177. | 3.0 | 3 |
| 273 | Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. Journal of Clinical Oncology, 2015, 33, 8078-8078. | 1.6 | 3 |
| 274 | Abstract CT124: NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC). Cancer Research, 2022, 82, CT124-CT124. | 0.9 | 3 |
| 275 | Clinical outcomes of stereotactic ablative radiotherapy in patients with pulmonary metastasis. Japanese Journal of Clinical Oncology, 2017, 47, 61-66. | 1.3 | 2 |
| 276 | A newly developed capture-based sequencing panel for genomic assay of lung cancer. Genes and Genomics, 2020, 42, 751-759. | 1.4 | 2 |
| 277 | YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. Journal of Clinical Oncology, 2018, 36, 9033-9033. | 1.6 | 2 |
| 278 | Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. Chinese Clinical Oncology, 2019, 8, 27-27. | 1.2 | 2 |
| 279 | Lazertinib, a 3<sup>rd</sup> generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.. Journal of Clinical Oncology, 2019, 37, 9037-9037. | 1.6 | 2 |
| 280 | Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 434-434. | 1.6 | 2 |
| 281 | Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-NaÃ¯ve Patients with ALK+ Nonâ€“Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. Cancer Research and Treatment, 2023, 55, 83-93. | 3.0 | 2 |
| 282 | Clinical Significance of Downstaging in Patients With Limited-Disease Small-Cell Lung Cancer. Clinical Lung Cancer, 2014, 15, e1-e6. | 2.6 | 1 |
| 283 | Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, 8108-8108. | 1.6 | 1 |
| 284 | A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.. Journal of Clinical Oncology, 2014, 32, TPS8124-TPS8124. | 1.6 | 1 |
| 285 | Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.. Journal of Clinical Oncology, 2017, 35, 8547-8547. | 1.6 | 1 |
| 286 | Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study.. Journal of Clinical Oncology, 2019, 37, 2558-2558. | 1.6 | 1 |
| 287 | ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).. Journal of Clinical Oncology, 2020, 38, 9601-9601. | 1.6 | 1 |
| 288 | Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A <i>Post Hoc</i> Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Research and Treatment, 2016, 48, 458-464. | 3.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7566-7566. | 1.6 | 1 |
| 290 | Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761).. Journal of Clinical Oncology, 2016, 34, e20507-e20507. | 1.6 | 1 |
| 291 | Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naÃ¯ve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status.. Journal of Clinical Oncology, 2016, 34, 9081-9081. | 1.6 | 1 |
| 292 | Cumulative incidence rates for CNS and non-CNS progression by baseline CNS metastases status using data from two alectinib phase II studies.. Journal of Clinical Oncology, 2016, 34, 9063-9063. | 1.6 | 1 |
| 293 | Detecting ALK fusions in lung cancer: multiple choice testing?. Lung Cancer Management, 2013, 2, 173-175. | 1.5 | 0 |
| 294 | A Case of Extranodal NK/T Cell Lymphoma, Nasal Type Involving Anus. The Korean Journal of Hematology, 2005, 40, 192. | 0.7 | 0 |
| 295 | Response of chemoradiation therapy after induction chemotherapy failure in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).. Journal of Clinical Oncology, 2012, 30, 5552-5552. | 1.6 | 0 |
| 296 | A phase II trial of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) for previously untreated stage I, II extranodal natural killer/T-cell lymphoma, nasal type (NTCL): A multicenter study of the Korean Cancer Study Group.. Journal of Clinical Oncology, 2013, 31, 8521-8521. | 1.6 | 0 |
| 297 | Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. Journal of Clinical Oncology, 2013, 31, 2098-2098. | 1.6 | 0 |
| 298 | The incidence, risk factors and prognostic implications of venous thromboembolism in Asian patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 1590-1590. | 1.6 | 0 |
| 299 | Clinical significance of downstaging in patients treated with chemoradiotherapy for limited-disease small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, e18555-e18555. | 1.6 | 0 |
| 300 | Cancer care near the end of life (EOL) in the era of molecular-targeted agents: Changes of trend during 10 years at single institution.. Journal of Clinical Oncology, 2014, 32, 9543-9543. | 1.6 | 0 |
| 301 | Effect of induction chemotherapy (IC) on survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) treated with chemoradiotherapy: Single center experience.. Journal of Clinical Oncology, 2014, 32, e17032-e17032. | 1.6 | 0 |
| 302 | Predictive and prognostic values of post chemoradiotherapy PET/CT and the effect of salvage surgery on survival in head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2015, 33, 6052-6052. | 1.6 | 0 |
| 303 | Poor prognostic factors in human papilloma virus-positive head and neck cancer: Who should not be candidate of de-escalated treatment?. Journal of Clinical Oncology, 2016, 34, 6078-6078. | 1.6 | 0 |
| 304 | Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.. Journal of Clinical Oncology, 2016, 34, e20520-e20520. | 1.6 | 0 |
| 305 | Korean Cancer Patientsâ€™ Awareness of Clinical Trials: Perceptions on the benefit and willingness to participate.. Journal of Clinical Oncology, 2016, 34, 10067-10067. | 1.6 | 0 |
| 306 | Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea.. Journal of Clinical Oncology, 2017, 35, 92-92. | 1.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Korean Journal of Internal Medicine, 2016, , . | 1.7 | 0 |
| 308 | Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC. Cancer Research, 2022, 82, 5477-5477. | 0.9 | 0 |